06.01.23
Cube Labs S.p.A. (“Cube Labs” or “Company”), an Italian venture builder in the healthcare technologies sector and listed on the Euronext Growth Milan market, segment Professional – has announced the signing of a service agreement between Biodiapers Srl, a company controlled by Cube Labs S.p.A., and Sicam Srl, an Italian industrial operator in the development of nonwoven fabrics and absorbent technology with multiple plants in numerous countries in America, Europe, the Middle East and Asia.
Biodiapers, established in 2018, is an innovative start-up that develops absorption technologies cleantech for babies, women and the elderly. Biodiapers is controlled by Cube Labs S.p.A. directly to 50.4% of the share capital and indirectly to 33.22% of the share capital through the trust of which the same Cube Labs S.p.A. is the sole beneficiary. The technology is based on clay microparticles, 100% natural, designed to absorb urine and reduce the incidence of adverse skin reactions and skin infections in the urinary tract. The peculiarity of Biodiapers lies in the use of the properties of clay and other materials that are completely biodegradable natural products that respect the environment, reducing the enormous environmental impact of conventional diapers, which take hundreds of years to decompose. Biodiapers owns n.1 patented technology on international markets.
The agreement provides, with a view to evaluating possible developments of new products for the B2B market, the provision of professional services by Sicam Srl aimed at developing the "core" of a product belonging to the line of adult, feminine and baby clay-based absorbents, and in particular of the definition of the prototype and its structure, of the relative industrial drawings and definition of the materials and technologies necessary for the realization of the subsequent finished industrial prototype (the "prototype of Core").
“We are proud to have signed this agreement with Sicam, a leading industrial company which
will allow the versatile and innovative solutions developed by Biodiapers to take an important step towards the commercial market," comments Filippo Surace, CEO and founder of Cube Labs. “We have great confidence in the commercial potential of our cleantech-based technologies clay microparticles, essential for the development of a new generation of absorbent products [that are ] hypoallergenic, safe and effective.”
The agreement has a duration of seven months and expires on December 31, 2023, for an amount of 22,000 euros plus VAT, and is preparatory to the definition of any subsequent commercial agreement concerning the future industrialization of the Core, through identification of the technology and development of the pilot plant, and subsequent marketing of the finished industrial prototype. As part of this possible new agreement, subject to the success of the aforementioned services and for the creation of the “Core prototype,” a budget of 70,000 euros has already been defined VAT for testing the “Core prototype” at third-party testing facilities for development purposes of the corresponding prototype suitable for production and marketing.
Biodiapers, established in 2018, is an innovative start-up that develops absorption technologies cleantech for babies, women and the elderly. Biodiapers is controlled by Cube Labs S.p.A. directly to 50.4% of the share capital and indirectly to 33.22% of the share capital through the trust of which the same Cube Labs S.p.A. is the sole beneficiary. The technology is based on clay microparticles, 100% natural, designed to absorb urine and reduce the incidence of adverse skin reactions and skin infections in the urinary tract. The peculiarity of Biodiapers lies in the use of the properties of clay and other materials that are completely biodegradable natural products that respect the environment, reducing the enormous environmental impact of conventional diapers, which take hundreds of years to decompose. Biodiapers owns n.1 patented technology on international markets.
The agreement provides, with a view to evaluating possible developments of new products for the B2B market, the provision of professional services by Sicam Srl aimed at developing the "core" of a product belonging to the line of adult, feminine and baby clay-based absorbents, and in particular of the definition of the prototype and its structure, of the relative industrial drawings and definition of the materials and technologies necessary for the realization of the subsequent finished industrial prototype (the "prototype of Core").
“We are proud to have signed this agreement with Sicam, a leading industrial company which
will allow the versatile and innovative solutions developed by Biodiapers to take an important step towards the commercial market," comments Filippo Surace, CEO and founder of Cube Labs. “We have great confidence in the commercial potential of our cleantech-based technologies clay microparticles, essential for the development of a new generation of absorbent products [that are ] hypoallergenic, safe and effective.”
The agreement has a duration of seven months and expires on December 31, 2023, for an amount of 22,000 euros plus VAT, and is preparatory to the definition of any subsequent commercial agreement concerning the future industrialization of the Core, through identification of the technology and development of the pilot plant, and subsequent marketing of the finished industrial prototype. As part of this possible new agreement, subject to the success of the aforementioned services and for the creation of the “Core prototype,” a budget of 70,000 euros has already been defined VAT for testing the “Core prototype” at third-party testing facilities for development purposes of the corresponding prototype suitable for production and marketing.
